By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German chemoproteomics firm Cellzome today announced a collaboration with Pfizer to study epigenetic mechanisms involved in stem cell differentiation.

Cellzome will use its Episphere platform to characterize epigenetic changes while Pfizer's Pain & Sensory Disorders and Regenerative Medicine unit, Neusentis, will provide expertise in stem-cell handling and regenerative medicine.

Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.